Galili N - Search Results

1

Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T-cell expansion.

Wang SA, Yue G, Hutchinson L, Landry ML, Hasserjian RP, Hao S, Galili N, Raza A, Woda BA. Wang SA, et al. Among authors: galili n. Br J Haematol. 2007 Jul;138(2):271-5. doi: 10.1111/j.1365-2141.2007.06648.x. Epub 2007 Jun 3. Br J Haematol. 2007. PMID: 17542981 Free article. No abstract available.

2

Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.

Galili N, Raza A. Galili N, et al. Best Pract Res Clin Haematol. 2009 Jun;22(2):223-37. doi: 10.1016/j.beha.2009.04.006. Best Pract Res Clin Haematol. 2009. PMID: 19698930

3

The biology and treatment of myelodysplastic syndromes.

Raza A, Galili N. Raza A, et al. Among authors: galili n. Rinsho Ketsueki. 2013 Oct;54(10):1730-6. Rinsho Ketsueki. 2013. PMID: 24064823 Review. No abstract available.

4

Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.

Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, Woda BA, Raza A, Wang SA. Yue G, et al. Among authors: galili n. Leuk Res. 2008 Apr;32(4):553-8. doi: 10.1016/j.leukres.2007.08.006. Epub 2007 Sep 20. Leuk Res. 2008. PMID: 17888511

5

Prognosis in myelodysplastic syndromes: are the new classifications useful?

Galili N, Raza A. Galili N, et al. Curr Hematol Malig Rep. 2008 Jan;3(1):19-22. doi: 10.1007/s11899-008-0004-z. Curr Hematol Malig Rep. 2008. PMID: 20425442

6

Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.

Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y, Zhao M, Galili N, Raza A, Medeiros LJ, Garcia-Manero G, Miranda RN. Wang SA, et al. Among authors: galili n. Leuk Res. 2011 Mar;35(3):351-7. doi: 10.1016/j.leukres.2010.07.018. Epub 2010 Aug 5. Leuk Res. 2011. PMID: 20691474

7

Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients.

Shetty V, Hussaini S, Alvi S, Joshi L, Shaher A, Dangerfield B, Nascimben F, Mundle S, Allampallam K, Reddy P, Galili N, Raza A. Shetty V, et al. Among authors: galili n. Br J Haematol. 2002 Mar;116(4):817-25. doi: 10.1046/j.0007-1048.2002.03366.x. Br J Haematol. 2002. PMID: 11886386 Free article.

8

Immunomodulatory drugs in myelodysplastic syndromes.

Galili N, Raza A. Galili N, et al. Expert Opin Investig Drugs. 2006 Jul;15(7):805-13. doi: 10.1517/13543784.15.7.805. Expert Opin Investig Drugs. 2006. PMID: 16787143 Review.

9

Defective ribosome biogenesis in myelodysplastic syndromes.

Galili N, Qasim SA, Raza A. Galili N, et al. Haematologica. 2009 Oct;94(10):1336-8. doi: 10.3324/haematol.2009.012021. Haematologica. 2009. PMID: 19794078 Free PMC article.

10

Pharmacotherapy of myelodysplastic syndromes.

Galili N, Raza A. Galili N, et al. Expert Opin Pharmacother. 2010 Aug;11(11):1889-99. doi: 10.1517/14656566.2010.485613. Expert Opin Pharmacother. 2010. PMID: 20486832 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters